Methods for the Effective Treatment of Metastatic Cancer

a metastatic cancer and effective treatment technology, applied in the field of metastatic cancer effective treatment, can solve the problems of inability to obtain complete response (crs) in patients with most types of metastatic cancer, few drug regimens give high rates of complete response in patients with metastatic cancer

Inactive Publication Date: 2015-09-24
GENERAL ONCOLOGY INC
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]The net effect of these activities is a profound sensitization of cancer cells to cell killing and inhibition of clonogenic survival by subsequent administration

Problems solved by technology

However, most common types of metastatic cancer are currently incurable.
Despite this truly massive scientific effort, obtaining complete response (CRs) in patients with most types of metastatic cancer has not been possible.
However, decreasing the tumor cell burden by 2-logs would still leave millions to billions of viable cancer cells in the patient, with time these cancer cells could multiply and cause progressive disease.
There have been tho

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the Effective Treatment of Metastatic Cancer
  • Methods for the Effective Treatment of Metastatic Cancer
  • Methods for the Effective Treatment of Metastatic Cancer

Examples

Experimental program
Comparison scheme
Effect test

embodiment e1

[0193]Embodiment E1 of the present invention is a method for obtaining CRs and durable, long-term CRs in patients with refractory metastatic cancers wherein the method is comprised of the administration of a set of one or more drugs that irreversibly inhibit the potential for cancer cell proliferation.

embodiment ee1

[0194]Embodiment Ee1 of the present invention is a set of drugs for use in a regimen for the treatment of refractory metastatic cancers and to obtain high rates of complete responses and durable, long-term complete responses in patients, wherein said set of drugs irreversibly inhibit the potential for cancer cell proliferation.

[0195]E1 can be expressed in an essentially equivalent form, as a method for obtaining high probabilities of a CR and a durable, long-term CR in a patient with refractory metastatic cancer, wherein said method is comprised of the administration of a set of one or more drugs that irreversibly and permanently inhibit the potential for cancer cell proliferation. Non-refractory metastatic cancers are generally sensitive to chemotherapy. While refractory metastatic cancers are generally resistant to chemotherapy. An effective treatment of refractory metastatic cancer would necessarily be an effective treatment for non-refractory metastatic cancer. The evolutionary ...

embodiment e2

[0196]Embodiment (E2) of the present invention is a method for the effective treatment of non-refractory metastatic cancer comprised of the administration of a set of one or more drugs, wherein said set of drugs irreversibly inhibits the potential for cancer cell proliferation and wherein said method gives improved patient outcome compared to current established therapies for the particular type of metastatic cancer.

Embodiment Ee2

[0197]Embodiment Ee2 of the present invention is a drug or set of drugs that irreversibly inhibit the potential for cancer cell proliferation for use in a regimen for the treatment of non-refractory metastatic cancers to achieve improved patient outcome compared to current established therapies for the particular type of metastatic cancer.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Login to view more

Abstract

The present invention relates to methods for the treatment of metastatic cancer. Methods of treating metastatic cancer by administration of a set of drugs overcome multiple mechanisms of melphalan resistance and hypersensitize cancer cells to melphalan are described. The methods involve the administration of drug(s) that induce oxidative stress in cancer cells, in conjunction with melphalan on a defined schedule.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 716,838, filed on Oct. 22, 2012. The entire teachings of the above application are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Combination chemotherapy has given high cure rates for certain types of metastatic cancer, such as childhood leukemia, lymphoma and testicular cancer. However, most common types of metastatic cancer are currently incurable. The 5-year survival rates of some metastatic cancers are approximately as follows: cervical 16%, colorectal 12.5%, uterine 16%, esophageal 3.5%, kidney 12.3%, liver / biliary 3%, lung / bronchus 3.9%, melanoma 16.1%, ovarian 27.3%, pancreatic 2%, stomach 3.9%, bladder 5.4%, breast 24.3%. (See: Frei E 3rd.; Curative cancer chemotherapy, Cancer Res. 1985; 45:6523-37 and Howlader N, et al.; SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, Md.).[0003]Despite decades of research and hundreds of bi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/198A61K38/05A61K35/28A61K31/138A61K31/175A61K38/07
CPCA61K31/704A61K31/175A61K31/198A61K38/05A61K35/28A61K31/138A61K38/07A61K31/5377A61K31/69A61P35/00A61K31/407A61K38/13A61K2300/00
Inventor GLAZIER, ARNOLD
Owner GENERAL ONCOLOGY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap